Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FertilityBlend

This article was originally published in The Tan Sheet

Executive Summary

"Nutritional supplementation may provide an attractive alternative or complement to conventional fertility therapy," according to a study published in the April Journal of Reproductive Medicine. The double-blind placebo-controlled study followed thirty women aged 24-46 who had tried unsucessfully to conceive for 6 to 36 months. Women received three capsules of either FertilityBlend or placebo per day for three menstrual cycles. After five months, five of the 15 women in the supplement group were pregnant compared to no pregnancies in the placebo group, Lynn Westphal, MD, Department of Obstetrics & Gynecology, Stanford University, et al. find. Daily Wellness Company's FertilityBlend contains chasteberry, l-arganine. An earlier study evaluating the supplement was announced in 2002 (1"The Tan Sheet" May 20, 2002, In Brief)...
Advertisement

Related Content

FertilityBlend study

Topics

Advertisement
UsernamePublicRestriction

Register

PS096773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel